- 1 Novel Domain V mutation in cfr-positive clinical Staphylococcus haemolyticus
- 2 isolates causing linezolid resistance in Egyptian ICU patients
- 4 Saber Maghraby<sup>1</sup>, Mohamed Ez El-Din Dawoud<sup>1</sup>, Mohamed Eweis<sup>1</sup>, Abdullah El-
- 5 nagish<sup>2\*</sup>, Doaa Ghaith<sup>3</sup>
- 6 Department of Botany and Microbiology, Faculty of Science, Cairo University,
- 7 Cairo, Egypt

3

- 8 <sup>2</sup> Department of Botany and Microbiology, Faculty of Science, Sohag University,
- 9 82524 Sohag, Egypt
- 10 <sup>3</sup> Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo
- 11 University, Cairo, Egypt
- \*Corresponding author: ael.nagish@science.sohag.edu.eg

# 13 Abstract

- Linezolid resistance has become a focal point worldwide, particularly as
- 15 linezolid stands as one of the last resort antibiotics against multiple-drug resistant
- bacterial strains. Despite its critical importance, the situation in Egypt remains
- 17 relatively unexplored. As various linezolid resistance mechanisms have been
- 18 identified in staphylococci, our investigation aims to uncover the molecular
- 19 characteristics of staphylococci showing reduced susceptibility to Linezolid at Kasr-
- 20 El-Eini Teaching Hospital. Thirty isolates were investigated in this study. The
- 21 selected samples, identified by Vitek 2 system and confirmed by 16S rRNA, were
- 22 examined by disc diffusion method. Of the 30 isolates, two were confirmed as
- 23 linezolid resistant and screened for the presence of cfr gene and mutations in the

It is made available under a CC-BY 4.0 International license.

24 Domain V of the 23S rRNA gene. Both of the studied strains, identified as 25 Staphylococcus haemolyticus, SZ-2 and SZ-7 harbored two point mutations G2576T 26 and G2602T in the Domain V of the 23S rRNA gene. A novel G2694C mutation 27 reported for the first time was detected in strain SZ-7. The presence of cfr gene was confirmed in both isolates. Linezolid-resistant Staphylococcus haemolyticus had 28 29 emerged in ICU patients with prior antibiotic exposure. The exact role of the novel 30 G2694C mutation in linezolid resistance needs further investigations. The study 31 underscores the importance of proper surveillance of cfr-carrying strains in the 32 healthcare settings in Egypt.

# Keywords

33

36

37

38

39

40

41

42

43

44

45

46

47

- 34 Linezolid, Resistance, Domain V, 23S rRNA, Mutations, Staphylococcus
- 35 haemolyticus

### Introduction

Staphylococcus haemolyticus, a coagulase-negative staphylococci (CoNS), naturally resides in the human skin tissue microbiota with the potential to induce various illnesses, such as skin infections, bloodstream infections, and other several nosocomial infections [1]. In recent years, broad-spectrum antibacterials were widely used in clinical settings, that led to a persistent rise in drug resistance. The current surge in bacterial drug resistance is a cause for serious concern [2]. Linezolid, an oxazolidinone antibiotic, was approved for clinical use in 2000 [3]. This antibiotic is potent against multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and Streptococcus pneumoniae [4]. Activity of linezolid results from binding to the 23S rRNA in the 50S ribosomal subunit. Thus, it acts as an inhibitor of protein

synthesis by binding to the ribosomal peptidyl transferase center (PTC) affecting tRNA positioning and eventually stopping the growth of bacteria [5,6].

The prevalence of linezolid resistance is steadily on the rise due to the extensive utilization of this antibiotic. Numerous reports have documented cases of linezolid-resistant staphylococci. The most well-established mechanisms underlying the development of linezolid-resistant staphylococci involves a mutation in the 23S rRNA gene target and the acquisition of the chloramphenicol-florfenicol resistance (cfr) gene [7,8,9,10]. The 23S rRNA, a constituent of the bacterial ribosome 50S subunit, can undergo mutations during exposure to linezolid, rendering the drug ineffective and ultimately resulting in drug resistance. Additionally, gene mutation sites exhibit variability among different strains [10, 11]. Among Staphylococcus strains, G2576T gene mutation is the most prevalent [11,12,13,14]. cfr gene, first identified in plasmids of Staphylococcus isolates from German cows, encodes a methyltransferase capable of modifying 23S rRNA [15]. The cfr gene facilitates methylation at specific sites on the ribosomal large subunit, leading to resistance against linezolid [5,16].

At our Kasr-El-Eini Teaching Hospital, the escalating concern lies in staphylococcal isolates in the intensive care units, which exhibit an extraordinary predisposition to develop resistance to all available antibiotics including linezolid. Consequently, in pursuit of viable treatment alternatives, there is a pressing need to comprehend the resistance mechanism of such isolates. Henceforth, this study was undertaken to investigate the molecular characteristics of linezolid-resistant S. haemolyticus identified in clinical infections. A collection of linezolid-resistant CoNS (LRCoNS) from 30 patients were evaluated for mechanisms of linezolid resistance.

# **Materials and Methods**

# Sample collection, identification and antimicrobial susceptibility testing of

#### bacterial isolates

Over two years; from March 2020 to March 2022, a total of 30 clinical isolates of staphylococci showing reduced susceptibility to Linezolid were collected from Kasr El-Eini Teaching Hospital. Samples were isolated from different specimens, including pus and blood. Disc diffusion method was used to screen isolates for linezolid resistance. Linezolid concentration used was 30 µg. The antimicrobial discs were obtained from Oxoid Ltd (Basingstoke, Hampshire, England, UK) and processed according to the manufacturer's instructions.

The identification of isolates was performed using conventional techniques such as cultivation on mannitol salt agar [17] and deoxyribonuclease (DNase) agar [18]. The isolates were further identified using VITEK 2 system (bioMérieux, Marcy-l'Étoile, France) using the VITEK 2 GP Card according to the manufacturer's instructions. The antibiotic susceptibility test of isolates was performed on Mueller Hinton agar using the Kirby Bauer disc diffusion method [19] as per Clinical and Laboratory Standard Institute [20] guidelines using antibiotic Linezolid 30 µg. Subsequently, identification of the selected bacterial isolates was confirmed by 16S rRNA gene [21]. All the relevant clinical data were collected for analysis, including dose and length of linezolid treatments and other results of antimicrobial susceptibility tests.

# Mechanisms of linezolid resistance among the isolates

The two most resistant *Staphylococcus haemolyticus* strains (namely SZ-2 and SZ-7) were selected and screened for point mutations in Domain V of the 23S rRNA

gene and the presence of the *cfr* gene by PCR and DNA sequencing as described previously [7,8,9,10].

The genomic DNA was isolated using Quick-DNA<sup>TM</sup> Miniprep Kit from Zymo Research<sup>TM</sup> according to the manufacturer instruction manual. Amplification was performed using the following PCR conditions: 35 cycles of denaturing, annealing, and extension at 94°C (30 s), 55°C (30 s), and 72°C (1 min) respectively; and a final 10-min extension at 72°C.

To elucidate the mechanism of linezolid resistance, screening for cfr gene and point mutations in domain V of 23S rRNA gene were investigated by amplifying the loci using the PCR conditions described by Yoo et al [8]. Amplification by PCR was performed using primers listed in Table 1. Amplicons were sequenced on both strands and sequences were aligned with the corresponding sequences from linezolid-susceptible *S. haemolyticus* JCSC 1435 (GenBank accession No. AP006716). All sequenced data was uploaded to the NCBI under accession numbers shown in the data availability section.

# **Table 1.** Primers are used for PCR amplification of targeted genes.

Target	Primer name	Sequence (5´-3´)	Product	Reference
genes			size (bp)	
Domain	23S_rRNA_Fw	5′-GCGGTCGCCTCCTAAAAG-3′	390	
V of the 23S	23S_rRNA_Rv	5'-ATCCCGGTCCTCTCGTACTA-3'		[22]
rRNA				
cfr gene	cfr-Fw	5′-TGAAGTATAAAGCAGGTTGGGAGTCA-3′	746	[23]
	cfr-Rv	5'-ACCATATAATTGACCACAAGCAGC-3'		

**Results and Discussion** 

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

Twenty four of the total 30 isolates were found to be totally susceptible to linezolid. Isolates SZ-2 and SZ-7, showed the highest resistance to linezolid, were selected for further investigations. The two isolates were identified as Staphylococcus based on their characteristic growth on blood agar and microscopic observations. The isolates were negative for mannitol fermentation, DNase and coagulase test, thus confirming coagulase negative Staphylococcus. The Vitek 2 system identified the isolates correctly (Table 2), with a probability of 99% and confidence level 'excellent'. The 16S rRNA gene sequence revealed that the isolates are S. haemolyticus with 99% similarity with S. haemolyticus strain JCSC1435 in BLAST search. Strain SZ-2, with a linezolid inhibition zone diameter (IZD) less than 1 mm (zone diameter breakpoint according to CLSI 2023 ≤ 20 mm), was found to have G2576T and G2602T mutations in the Domain V of 23S rRNA gene (Table 2). A novel G2694C mutation in addition to the same two G2576T and G2602T mutations, both in domain V of the 23S rRNA gene, were identified in S. haemolyticus strain SZ-7 with a linezolid IZD less than 1 mm. Previous studies have already reported the G2576T and G2602T substitutions in the Domain V of the 23S rRNA gene of linezolid-resistant Staphylococcus spp. [2,7,12,13,14,24]. Although both mutations were first reported in 2007 and in 2021, respectively [2,25], this is the first report of these mutations in S. haemolyticus isolated in Egypt. The novel mutation G2694C, whether it plays a role in linezolid resistance is uncertain and needs further confirmation. Nevertheless, this revelation

may have the potential to contribute valuable insights into investigating the mechanism of linezolid resistance caused by mutations in the V domain of 23S rRNA gene.

cfr gene in both isolates was detected and confirmed by sequencing the amplicons on both strands. At Kasr-El-Eini Teaching Hospital, isolations of a cfr-carrying clinical S. haemolyticus isolates from the ICU units is extremely alerting to us. Our greatest concern is the presence of the cfr gene in both isolates, as its minimal fitness cost allows cells to retain it even in the absence of selection pressure from the antibiotic. Typically, the cfr gene is situated in an unstable genetic environment, either on the chromosome or on multidrug-resistant plasmids [26]. This precarious positioning would facilitate the easy spread of cfr into susceptible populations and other pathogenic bacteria. Moreover, cfr-mediated resistance confers resistance to a wide-spectrum of antibiotics not only linezolid and thus poses a significant challenge to therapeutic options.

Table (2): Mutations detected in the V domain of 23S rRNA gene of the resistant isolates *S. haemolyticus strain SZ-2* and SZ-7.

Strain	ICU	Clinical	Vitek 2		Coagulase	Mutations	MIC	Linezolid	cfr
		sample	results		test	of the	(µg/mm)	IZD	gene
			P	C.L		Domain V	Linezolid	(CLSI	
			(%)			of		2023)	
						23S rRNA			
						gene			
SZ-2	Yes	Blood	99	Е	Negative	G2576T,	30 μg	< 1 mm	+
						G2602T			
SZ-7	Yes	Blood	99	Е	Negative	G2576T,	30 μg	< 1 mm	+
						G2602T,			

It is made available under a CC-BY 4.0 International license.

G2694C 152 P = Probability, C.L = Confidence Level, E = Excellent, IZD = Inhibation zone 153 diameter; Mutations in 23S rRNA according to Staphylococcus numbering 154 (NR 076257.1) 155 Although linezolid resistance due to mutations in Domain V of the 23S rRNA 156 and presence of cfr gene were reported in several staphylococcal species form many countries around the world such as Spain [27], the USA [28], Brazil [29], Mexico [30], 157 158 and Korea [32], this is the first report of these mutations in S. Japan [31] 159 haemolyticus isolated in Egypt. This first emergence of LRSH in intensive care units 160 in our hospital during a short period is very worrying, requiring serious measures and 161 proper surveillance in the healthcare settings to prevent the intrahospital 162 dissemination of resistant strains. The novel G2694C mutation in Domain V of the 163 23S rRNA, whether it plays a role in linezolid resistance is uncertain and needs 164 further confirmation. Nevertheless, this revelation may have the potential to 165 contribute valuable insights into investigating the mechanism of linezolid resistance 166 caused by mutations in Domain V of the 23S rRNA. The study emphasizes the need 167 for proper surveillance of cfr-carrying strains in the healthcare settings in Egypt. 168 Data availability 169 All sequenced data was uploaded to the NCBI under accession numbers PP525131-170 PP525132 for cfr genes and PP506638- PP506639 for 23S ribosomal RNA gene of S. 171 haemolyticus strain SZ-2 and SZ-7 respectively. 172 Acknowledgements 173 Not applicable.

**Ethical approval** 

175 Ethical approval was granted by the Review Board of the Clinical and Chemical 176 Pathology Department, Faculty of Medicine, Cairo University, Egypt prior to the 177 beginning of the study with a waiver of informed consents. 178 Disclosure statement The authors declare that there are no conflicts of interest. 179 180 **Funding** 181 Not applicable. **ORCID** 182 183 Abdullah El-nagish: https://orcid.org/0000-0002-5704-5475 184 References 185 [1] Czekaj, T., Ciszewski, M., & Szewczyk, E. M. (2015). Staphylococcus 186 haemolyticus – An emerging threat in the twilight of the antibiotics age. 187 Microbiol. (United Kingdom, 161, 2061–2068. [2] Gostev, V., Leyn, S., Kruglov, A., Likholetova, D., Kalinogorskaya, O., Baykina, 188 189 M., & Sidorenko, S. (2021). Global expansion of linezolid-resistant coagulase-190 negative staphylococci. Frontiers in Microbiology, 12, 661798. 191 [3] Kehrenberg, C., Schwarz, S., Jacobsen, L., Hansen, L. H., & Vester, B. (2005). A 192 new mechanism for chloramphenicol, florfenicol and clindamycin resistance: 193 Methylation of 23S ribosomal RNA at A2503. *Molecular microbiology*, 57(4), 194 1064–1073. 195 [4] Giessing, A. M. (2009). Identification of 8-methyladenosine as the modification 196 catalyzed by the radical SAM methyltransferase Cfr that confers antibiotic 197 resistance in bacteria. RNA, 15, 327–336.

198 [5] Long, K. S., & Vester, B. (2012). Resistance to linezolid caused by modifications 199 at its binding site on the ribosome. Antimicrobial Agents and Chemotherapy, 200 *56*(2), 603–612. 201 [6] Sadowy, E. (2018). Linezolid resistance genes and genetic elements enhancing 202 their dissemination in enterococci and streptococci. Plasmid. 203 [7] Zhou, W., Niu, D., Gao, S., Zhong, Q., Liu, C., Liao, X., & Shen, H. (2023). Prevalence, biofilm formation, and mass spectrometric characterization of 204 205 linezolid-resistant Staphylococcus capitis isolated from a tertiary hospital in 206 China. *Journal of Global Antimicrobial Resistance*, 33, 155–163. 207 [8] Yoo, I. Y., Kang, O. K., Shim, H. J., Huh, H. J., & Lee, N. Y. (2020). Linezolid 208 resistance in methicillin-resistant Staphylococcus aureus in Korea: High rate 209 of false resistance to linezolid by the VITEK 2 system. Annals of Laboratory 210 Medicine, 40(1), 57–62. [9] Han, X., Zou, G., Liu, J., Yang, C., Du, X., Chen, G., & Jiang, X. (2022). 211 212 Mechanisms of linezolid resistance in Staphylococcus capitis with the novel mutation C2128T in the 23S rRNA gene in China. BMC Microbiology, 22(1), 213 203. 214 215 [10] Maarouf, L., Omar, H., El-Nakeeb, M., & Abouelfetouh, A. (2021). Prevalence 216 and mechanisms of linezolid resistance among staphylococcal clinical isolates 217 from Egypt. European Journal of Clinical Microbiology & Infectious 218 Diseases, 40, 815–823. [11] Almeida, L. M., Lincopan, N., Araújo, M. R. E., & Mamizuka, E. M. (2012). 219 220 Clonal dissemination of linezolid-resistant Staphylococcus haemolyticus 221 exhibiting the G2576T mutation in the 23S rRNA gene in a tertiary care 222 hospital in Brazil. Antimicrobial Agents and Chemotherapy, 56(5), 2792.

- 223 [12] Balandin, B., Lobo, B., Orden, B., Román, F., García, E., Martínez, R., ... &
- Galdos, P. (2016). Emergence of linezolid-resistant coagulase-negative
- staphylococci in an intensive care unit. *Infectious Diseases*, 48(5), 343-349.
- [13] Hegstad, K., Longva, J. Å., Hide, R., Aasnæs, B., Lunde, T. M., & Simonsen, G.
- S. (2014). Cluster of linezolid-resistant Enterococcus faecium ST117 in
- Norwegian hospitals. Scandinavian journal of infectious diseases, 46(10),
- 229 712-715.
- 230 [14] Mazzariol, A., Kocsis, E., Bragagnolo, L., Pellizzer, G., Rassu, M., & Cornaglia,
- G. (2012). Co-infection by two linezolid-resistant coagulase-negative
- staphylococci with two different resistance determinants. Scandinavian
- *journal of infectious diseases*, 44(12), 978-981.
- 234 [15] Toh, S.-M. (2007). Acquisition of a natural resistance gene renders a clinical
- strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic
- antibiotic linezolid. *Mol. Microbiol*, *64*, 1506–1514.
- 237 [16] LaMarre, J. M., Locke, J. B., Shaw, K. J., & Mankin, A. S. (2011). Low fitness
- cost of the multidrug resistance gene cfr. Antimicrob. Agents Chemother, 55,
- 239 3714–3719.
- 240 [17] Kateete, D. P., Kimani, C. N., Katabazi, F. A., Okeng, A., Okee, M. S., &
- Nanteza, A. (2010). Identification of Staphylococcus aureus: DNase and
- Mannitol salt agar improve the efficiency of the tube coagulase test, Ann.
- 243 Clin. Microb. Antimicrob, 9, 23.
- 244 [18] Boerlin, P., Kuhnert, P., Hussy, D., & Schaellibaum, M. (2003). Methods for
- identification of Staphylococcus aureus isolates in cases of bovine mastitis. J
- 246 *Clin Microbiol*, *41*, 767–771.
- 247 [19] Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol.

248 *American society for microbiology*, 15, 55–63. 249 [20] CLSI, M. (2023). Performance Standards for Antimicrobial Susceptibility 250 Testing (33rd ed.). [21] White, T. J., Bruns, T., Lee, S. J. W. T., & Taylor, J. (1990). Amplification and 251 252 direct sequencing of fungal ribosomal RNA genes for phylogenetics. PCR 253 *Protocols: A Guide to Methods and Applications*, 18, 315–322. [22] Meka, V. G., Pillai, S. K., Sakoulas, G., Wennersten, C., Venkataraman, L., & 254 255 DeGirolami, P. C. (2004). Linezolid resistance in sequential Staphylococcus 256 aureus isolates associated with a T2500A mutation in the 23S rRNA gene and 257 loss of a single copy of rRNA. J Infect Dis, 190, 311–317. 258 [23] Lee, S. M., Huh, H. J., Song, D. J., Shim, H. J., Park, K. S., & Kang, C. I. (2017). 259 Resistance mechanisms of linezolid-nonsusceptible enterococci in Korea: Low 260 rate of 23S rRNA mutations in Enterococcus faecium. J Med Microbiol, 66, 261 1730–1735. 262 [24] Almeida, L. M., Araújo, M. R. E., Sacramento, A. G., Pavez, M., Souza, A. G., Rodrigues, F., & Mamizuka, E. M. (2013). Linezolid resistance in Brazilian 263 264 Staphylococcus hominis strains is associated with L3 and 23S rRNA 265 ribosomal mutations. Antimicrobial Agents and Chemotherapy, 57(8), 4082. 266 [25] Tarazona, R. E. R., Padilla, T. P., Gómez, J. C. S., Sánchez, J. E. G., & 267 Hernandez, M. S. (2007). First report in Spain of linezolid non-susceptibility 268 in a clinical isolate of Staphylococcus haemolyticus. International Journal of 269 Antimicrobial Agents, 3(30), 277-278. 270 [26] Gopegui, E. R., Juan, C., Zamorano, L., Perez, J. L., & Oliver, A. (2012). 271 Transferable multidrug resistance plasmid carrying cfr associated with tet(L), 272 ant (4')-Ia, and dfrK genes from a clinical methicillin resistant Staphylococcus

273 aureus ST125 strain. Antimicrob Agents Chemother, 56, 2139–2142. 274 [27] Morales Kucharski, M. G., Picazo, J. J., Baos, E., Candel, F. J., Arribi, A., Peláez 275 Ros, B., & Sánchez García, M. (2010). Resistance to linezolid is mediated by 276 the cfr gene in the first report of an outbreak of linezolid-resistant 277 Staphylococcus aureus. 278 [28] Bonilla, H., Huband, M. D., Seidel, J., Schmidt, H., Lescoe, M., McCurdy, S. P., Quinn, J. P. (2010). Multicity outbreak of linezolid-resistant 279 280 Staphylococcus epidermidis associated with clonal spread of a cfr-containing 281 strain. Clinical Infectious Diseases, 51, 796–800. 282 [29] Gales, A. C., Sader, H. S., Andrade, S. S., Lutz, L., Machado, A., & Barth, A. L. 283 (2006). Emergence of linezolid-resistant Staphylococcus aureus during 284 treatment of pulmonary infection in a patient with cystic fibrosis. *International* 285 Journal of Antimicrobial Agents, 27, 300–302. 286 [30] Mendes, R. E., Deshpande, L., Rodriguez-Noriega, E., Ross, J. E., Jones, R. N., 287 & Morfin-Otero, R. (2010). First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: Evidence of in vivo cfr 288 289 mobilization. *Journal of Clinical Microbiology*, 48, 3041–3043. 290 [31] Ikeda-Dantsuji, Y., Hanaki, H., Sakai, F., Tomono, K., Takesue, Y., Honda, J., 291 Nonomiya, Y., Suwabe, A., Nagura, O., & authors. (2011). Linezolid-resistant 292 Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in 293 Japan. J Infect Chemother, 17, 45–51. 294 [32] An, D., Lee, M. Y., Jeong, T. D., Sung, H., Kim, M. N., & Hong, S. B. (2011). 295 Co-emergence of linezolid-resistant Staphylococcus aureus and Enterococcus 296 faecium in a patient with methicillin-resistant S. aureus pneumonic sepsis. 297 Diagnostic Microbiology and Infectious Disease, 69, 232–233.

It is made available under a CC-BY 4.0 International license .

298

299